We provide the first demonstration that RSV targets the immune evasion capacities of cancer cells by directly disrupting N-glycan branching and promoting dimerization of PD-L1, thereby impeding the correct localization of PD-L1 to the plasma membrane, preventing the PD-1 interaction surface of PD-L1 and, consequently, increasing the susceptibility of biologically aggressive cancer cells to T-cell-mediated cell death (Figure 9). The gene discussed is CD274; the disease is cancer.